| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 29/04/2024 | 22:16 | Business Wire | Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 24/04/2024 | 22:05 | Business Wire | Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 22/04/2024 | 15:04 | Business Wire | Acadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé Canada | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 22/04/2024 | 15:04 | Business Wire | Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 19/04/2024 | 22:05 | Business Wire | Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 17/04/2024 | 22:05 | Business Wire | Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 02/04/2024 | 22:05 | Business Wire | Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 01/04/2024 | 22:05 | Business Wire | Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 13/03/2024 | 21:05 | Business Wire | Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 12/03/2024 | 12:21 | IH Market News | Oracle Soars 13% With Exceptional Growth and Boosts Nvidia Shares With Collaboration Announcement, and More | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 11/03/2024 | 21:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 11/03/2024 | 21:05 | Business Wire | Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 29/02/2024 | 15:05 | Business Wire | Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024 | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 28/02/2024 | 00:13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 27/02/2024 | 22:05 | Business Wire | Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 14/02/2024 | 13:08 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 13/02/2024 | 22:05 | Business Wire | Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 08/02/2024 | 23:05 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 31/01/2024 | 02:48 | Business Wire | Acadia Announces Additions to Executive Team | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 26/01/2024 | 23:25 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 18/01/2024 | 22:05 | Business Wire | Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 21/12/2023 | 22:05 | Business Wire | Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 15/12/2023 | 18:46 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 14/12/2023 | 11:59 | IH Market News | Apple Stocks Reach Record, Adobe Faces Stock Drops, Berkshire Hathaway Increases Stake in OXY, and More | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 14/12/2023 | 03:24 | Business Wire | Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin) | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 13/12/2023 | 19:41 | Business Wire | Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 30/11/2023 | 15:05 | Business Wire | Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 27/11/2023 | 15:05 | Business Wire | Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 21/11/2023 | 23:00 | Business Wire | Acadia Pharmaceuticals Announces Change in Research and Development Leadership | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |
| 02/11/2023 | 21:05 | Business Wire | Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview | NASDAQ:ACAD | Acadia Pharmaceuticals Inc |